Drug intelligence / Profile preview

Gliopep

Development stage: Preclinical
Lead developer: Oncopeptides
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

Gliopep is a lipophilic peptide-drug conjugate (PDC) being developed by Oncopeptides for the treatment of glioblastoma. The drug is specifically engineered to penetrate the blood-brain barrier (BBB), a significant challenge in treating central nervous system malignancies. Utilizing Oncopeptides' proprietary PDC platform, Gliopep is designed to deliver a cytotoxic payload directly into tumor cells while minimizing systemic exposure. As of 2024, the program is in the research phase, with plans for a 'Window-of-Opportunity' clinical study. The Norwegian Directorate of Medical Products (DMP) has granted the program fast-track designation to accelerate its clinical development. The specific molecular target of the conjugate has not been publicly disclosed.

Other names: Gliopep

Beyond the preview

Go deeper on Gliopep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gliopep.

Explore the full profile